Carregant...

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience

BACKGROUND: Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial. PATIENTS AND METHODS. The medical documentation of 19 adult patients with recurre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Radiol Oncol
Autors principals: Mesti, Tanja, Moltara, Maja Ebert, Boc, Marko, Rebersek, Martina, Ocvirk, Janja
Format: Artigo
Idioma:Inglês
Publicat: Versita, Warsaw 2015
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4362611/
https://ncbi.nlm.nih.gov/pubmed/25810706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/raon-2014-0021
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!